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Dr Griepp. Tony, may I ask you a question? How difficult do
you think it is to sort out in your own experience with aortic
trauma, the delayed repair and the advent of thoracic endovascular
aortic repair (TEVAR)? Do you think if TEVAR hadn’t come
along, you would be having these same results with open repair
at this point, just by having added the delayed repair for those
patients who can have the delay?
Dr Estrera. It is very complicated to sort out. When we pub-
lished this article a couple of years ago, the only variable that
was protective in multivariable analysis was actually delayed re-
pair; TEVAR was not. Now, after having added another 35 cases
or so, I have to think that TEVAR might play a role. But it is
very difficult.
And I didn’t give credit where credit is due, to be honest with
you, because a lot of the improvements should take into consider-
ation the trauma team and all the advancements that have occurred
in trauma care generally. In aortic trauma, we think about aortic in-
juries killing the patients. But the reality is that these patients have
a lot of other injuries, and there have been a lot of advancements in
trauma care during the past decade that also have contributed to
better outcomes. I don’t think that we should think or say that de-
layed repair or TEVAR is the only factor, and it is difficult to say
that the data really bear out such a claim at this point.
Another point in that original article that has changed now is the
fact that in our early experiencewe delayed repair in many of these
patients because they had an abnormal white blood cell count or
something else that we feared would cause a problem with graft
infections. Now, however, we have reduced the preintervention
hospital stay with TEVAR to about 1 day from the time the diag-
nosis is made. So as soon as that diagnosis is made, we rush the
patient up to the hybrid suite, put the TEVAR graft in, and repair
the aorta. Then the patient can go back to the trauma service,ures: Authors have nothing to disclose with regard to commercial support.
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DrGriepp. Let me just ask one other question. Dr Kouchoukos,
you are perhaps the biggest advocate here of using hypothermic
circulatory arrest for thoracoabdominal aortic aneurysms. Most
of the concerns expressed by people who are interested in explor-
ing this technique have to do with bleeding problems. So maybe
you can tell us just a little bit about how you deal with postopera-
tive bleeding and manage coagulation in these patients.
DrKouchoukos.Wedon’t do anything special. I think there has
always been a concern about bleeding, but the experience with hy-
pothermic circulatory arrest for ascending aortic disease and arch
disease has led us to feel more confident about using it in the
descending thoracic aorta. We use hypothermic circulatory arrest
exclusively in the descending aorta, and we also use it for thora-
coabdominal aneurysms.
I showed you some of the transfusion requirements. We looked
at them in general, and if you compare the blood requirements with
those for other perfusion techniques that have been used, they do
not exceed those requirements. We use fresh-frozen plasma; we
use platelets; we use cryoprecipitate. We have only used factor
VII in 1 or 2 cases in which the bleeding was extensive. So obvi-
ously we screen these people carefully preoperatively to be certain
that they don’t have coagulation problems, but bleeding has not in
general been a big problem.
DrGriepp.Do you have a routine of what you give at the end of
the operation, or does it depend on each patient?
Dr Kouchoukos. We have operated on several Jehovah’s Wit-
nesses to whom we haven’t given any blood products. We give
blood products on an as-needed basis. If the perfusion time has
been longer than 2 hours, we prophylactically give platelets and
fresh-frozen plasma, and occasionally cryoprecipitate, at the com-
pletion of the procedure.
Dr Manu N. Mathur (St Leonards, New South Wales, Aus-
tralia). This is a question for Professors Elefteriades and Sundt.
Is there any evidence at all for replacing the ascending aorta in pa-
tients with bicuspid valves when the bicuspid valve is fine, the root
is fine, and the ascending aortic aneurysm is smaller than 5 cm?
Dr Elefteriades. In all our analyses, we have taken the biggest
diameter of the aorta at any level, at the belly of the aneurysm if
you will. The management of an aneurysm in the ascending aorta
in a patient with a bicuspid valve can be decided on the basis of the
largest diameter at any level. Our studies at Yale have found that
the behavior of the ascending aorta in the patient with a bicuspidiovascular Surgery c Volume 145, Number 3S S159
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patient without a bicuspid valve. If you are getting into questions
of what to do if you are going in for the valve, or if you are going in
for the aorta, the questions of what should be done for the valve and
so on become more complicated. I think that most surgeons would
replace the aorta when they are going in for the valve when the
aorta is larger than 4.5 cm in diameter, and some when it is larger
than 4 cm.
Dr Leonardo Esteve Lima (Brasilia, Brazil). I have to congrat-
ulate Dr Roselli, and I have a question. We believe that technology
evolves and that we need expanding options, as you said. After
starting to use the Cook device, we switched to the Gore Excluder
C3 device for thoracoabdominal aneurysms, with a fenestrated
branch. It is faster to use and easier to maneuver. With this kind
of friendly device, we do believe that we can use it even for emer-
gency cases. We believe that the options have been expanded, and
one can use devices for more cases. What is your opinion about
that?
Dr Roselli. I don’t have any experience with that device. I think
that we are going to see all these devices becoming more valuable.
We have brought the Endologix device to our institution and have
been using that, but for elective cases. We have branch devices for
the arch that we have been using. I don’t have any experience with
the Gore fenestrating device, but I think as long as you are follow-
ing these patients up and you are confident that these repairs are
durable, it’s great. We study our experience closely, and there is
room for a lot of advancement.
Dr Lima. Just to give you an example, we took about an hour
and a half for an emergency trifurcated branch. That is very fast
compared to the Cook device, and so that’s why we don’t use
the Cook in some emergencies. What do you think about the time?
Dr Roselli. Well, for a 3-branch device in an abdominal aneu-
rysm, I saw Ed Bevins fix a rupture of a juxtarenal aneurysm in 15
minutes. So your hour and a half sounds long. But you have to look
at the question on a patient-to-patient basis. I think it is wonderful
if you can get good results with these devices. The important thing
is to understand the limitations of all of them and to be comfortable
with the particular device that you use.
Dr Jeffrey Gibson (Germantown, Tenn). Anthony, can you tell
me a little bit about how you manage your delayed patients med-
ically and how you ‘‘cooperate’’ (I guess that is a good word) with
the vascular surgeons in caring for these patients?
Dr Estrera. A good question. The way our department is set
up is that the vascular surgeons are also the cardiac surgeons and
the thoracic surgeons. So we all work together, and we discuss all
these cases. So it is not really an issue in our department, because
we have one head—Hazim Safi—and he directs everything else.
But with regard to the trauma service, it’s a good question. It has
almost become a moot point, to be frank with you. When we used
to delay these patients, and put the stents in later, cooperation was
an issue, and it was a complicated issue. The trauma service, espe-
cially in head injury, would want to maintain the pressures higher,
and we were trying to get the pressures down and administering
a b-blocker or anti-impulse therapy. It was very complicated at
that time.
What has simplified everything is that as soon as the patient gets
in and the diagnosis of aortic trauma is made, the patient is run up
to the operating room (the hybrid suite), and we deploy the stentS160 The Journal of Thoracic and Cardiovascular Surand fix the traumatic injury. And then the patient goes to the shock
trauma intensive care unit and is managed there, and we don’t limit
the blood pressure at that point. In fact, with our TEVAR experi-
ence, we don’t mind higher pressures, especially to prevent spinal
cord complications. So the advent of TEVAR has decreased our
use of delayed selective management at this point.
Mr Cheshire. Tony, can you just mention, with that policy,
whether you have had any acute graft collapses or failures?
Dr Estrera. The short answer is no. Again, we are very selec-
tive, and we have to make sure that we have good anatomic bound-
aries to put in the stent. Ali Azizzadeh, Kristofer Charlton-Ouw,
and Sheila Coogan are our vascular surgeons. We work together,
and these cases we discuss every time they occur and make deci-
sions together.
I can justify our policy of using devices in my mind because we
have seen a decrease in early mortality. I think I have done 1 open
repair in the last 3 years at our institution for traumatic aortic rup-
ture, because we just take the patients straight to the hybrid suite
for stent placement. This possibility has really changed how we
think about it. But, as Craig Miller said earlier, we need long-
term results, and the article that he presented on aneurysms is
very sobering. If there are any differences in mortality at 5 and
10 years, then I will rethink things. I can justify immediate stent
placement now, however, because we have shown a decrease in
the early mortality in this situation.
Dr Miller. Tony, I’m confused; help me. You just answered the
gentleman’s question by saying that TEVAR has now supplanted
your delayed permissive hypotension treatment. In the last year
or so, howmany patients are undergoing TEVARwithout thinking,
as is happening almost everywhere around the world? During the
last year or so, have you been doing anything except TEVAR?
Dr Estrera. In the last 3 years, we have done 1 case open. Sowe
have done everything with TEVAR; we do TEVAR immediately
after the injury. TEVAR has thus supplanted delayed selective
management. When we were doing the repairs open, we used to
delay these patients and get them in a little bit better physiologic
state if they didn’t have grade 4 ruptures or even severe grade 3
ruptures with large hematomas. The ones with ruptures or large he-
matomas, I’d operate on immediately.
Dr Miller. So the tide has swept you out with it?
Dr Estrera. It did when we analyzed these data. As Thor Sundt
said 6 years ago at this meeting about the denominator, we as sur-
geons live in the numerator: we only see what we do. We looked at
our overall admissions for traumatic aortic rupture, however, and I
saw that the mortality had decreased. I know it is not just the use of
TEVARearly, but the improving early results didmake a difference
in mymind. At this point, I accept the early use of TEVAR because
I think it helps in the initial postoperative period. But 5 to 10 years
out, if we start to see problems in a 20- or 30-year-old, I will re-
think our ideas and change.
DrMiller. Following up, didn’t you tell us that the multivariate
analysis showed that delayed surgical repair was protective in
terms of mortality, but TEVAR was not?
Dr Estrera. That’s correct.
Dr Miller. I hear some hypocrisy here.
Dr Estrera. That’s correct, yes.
Dr Miller. You are going to have a hard time following these
patients up, because, as you know, the best follow-up of any acutegery c March 2013
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the border patrol, the Drug Enforcement Agency, US Immigration
and Customs Enforcement. We just can’t follow these young folks
up.
Dr Estrera. But Craig, we looked at every patient, and with the
way we are managing them now, the mortality has decreased. It’s
hard for me, because these patients—as you know—are very sick.
They come in, and you do a big open operation, which is a good
technical operation but more invasive than TEVAR. These patients
are physiologically insulted: they have liver injury, they have
splenic injury, they have head injury, and they don’t do as well
as our elective descending thoracic aneurysm repair. They just
don’t. So I have justified early TEVAR in my mind, but I don’t dis-
agree with what you are saying. In the end, if we see a decrease in
long-term survival with TEVAR, then we will switch back to de-
layed open repair.
DrMiller. But the delayed treatment with an open surgical pro-
cedure 1, 2, or 3 weeks later, that’s definitive and it is low risk,
correct?
Dr Estrera. Potentially.
Dr Griepp. I’m going to let Mr Cheshire have the final
comment.
Mr Cheshire. I was just going to comment on being swept by
the wave and Dr Miller’s comments. In the United Kingdom, the
national data would suggest that only about 20% of thoracic aneu-
rysms are now repaired open: that ship has almost sailed from our
country.
Dr Griepp. Interesting. Let me just move to a slightly different
subject.
Drs Safi and Coselli have both published a lot of data having to
do with the impact of the status of renal function on operative mor-
tality and complications. I ask each of you, have you thought at all
about why this is and whether there is any way to change that when
you have got such a great marker? How do you move somebody
from a 30% risk to a 10% risk? Is it just a marker for poor
protoplasm?
Dr Safi.Well, we looked at it, and, as you said, it’s a marker. I
don’t know what the impact of our protection of the kidney is go-
ing to achieve. Dr Tray Miller is interested in that subject. But
apart from that, I think that if we can eliminate renal failure post-
operatively, we make our operation better than the endovascular.
Dr Coselli. We haven’t looked at glomerular filtration rate
(GFR) the sameway that Drs Estrera and Safi have, but I also think
it’s almost certainly a marker. One of the things that backs that up
is that we have seen many fewer type 1 aneurysms because of en-
dovascular work. We are still doing a sizable number of extent 2
aneurysms, but the really high-risk patients that we are facing
now are the elderly patients with type 3 and 4 aneurysms with
an enormous amount of superimposed atherosclerosis, who fre-
quently start with minimal or no renal function. I think that blends
into that whole process as an evolution of the risk profile, but we
haven’t really culled it out the way they have.
Dr Griepp. Do you think that all the renal dysfunction that you
are measuring as a risk factor is from atheroemboli or from hyper-
tension? Why are these patients so different?
Dr Coselli. I think it’s a combination of both. We think it’s
superimposed atherosclerosis. Many of these patients with type
3 and 4 lesions only have one kidney. Then there is another groupThe Journal of Thoracic and Cardof patients, which overlaps somewhat, who come in with ex-
tremely poor renal function but decent anatomy and have hyper-
tensive nephropathy so that their GFR is really quite low. But
the etiology of the hypertensive nephropathy has affected their or-
gan function elsewhere: not only has it impacted the kidneys, it has
increased the risks of stroke, myocardial infarction, and multiple
organ failure.
Dr Safi.When Dr Tray Miller looked into our thoracoabdomi-
nal and descending aneurysms, the patients with descending an-
eurysms have the best GFR. It is not normal, but it is 75 mL/
min. The worst GFR is with extent 4 aneurysms. And once the
viscera are involved with atheromatous plaque and aneurysm,
kidney function deteriorates. Probably, as Joe said, it is a combi-
nation. I think that microemboli go there and kill the kidneys. In
the literature, they say that extent 4 is best suited for stenting.
They can have these cases, with their low GFR. The average,
in our experience, is almost 50 mL/min, and these cases have
the highest mortality.
Dr ZiadHanhan (Jersey City, NJ). I have questions for Drs Safi
and Estrera. If you gentlemen, God forbid, had a traumatic aortic
rupture—isolated—how would you have that addressed for
yourself?
Dr Safi. If it comes to myself, I know what he is going to do. I
tell him to go and cut me and put a graft in, and I’m done. But I’m
sure he is going to cut my vocal cords so I can’t talk to him.
Dr Estrera. That’s a great question. Isolated, no other injury,
and Craig Miller will love to hear this, I would have a good sur-
geon—Dr Safi’s vocal cords don’t work anymore—so I would
have a good surgeon cut me open and just fix it so I’m done. I
don’t need any radiographs or computed tomographic (CT) scans
or anything for the rest of my life.
Dr Jehangir Appoo (Calgary, Alberta, Canada). I wanted to
ask Dr Elefteriades whether he has been able to extrapolate the
bench engineering work with strain and stress to some sort of in
vivo model to assess aortic wall strain and stress on CT to help
us clarify what has been discussed a lot today: which patients
should be operated on, and which patients shouldn’t, on the basis
of something more specific than diameter.
Dr Elefteriades. You bring up an absolutely superb point. Di-
ameter is good, but there has got to be more, and I think genes
and engineering are the more that we want to achieve. And there
are efforts under way. I was talking with Pria from Papworth about
this and some others also. There are efforts underway to quantitate
wall stress based on CT scan or magnetic resonance imaging. I
think that it is important to realize that when you get down to look-
ing at those equations, there are assumptions that are made that
may not be realistic or may limit accuracy.
One such assumption is the blood pressure. The blood pressure
is checked by cuff sometime before the examination is done, and
then it is presumed to be steady during the examination. We all
know from the operating room that this is not true. And then, if I
am correct, most of the equations assume the elastic modulus of
the patient’s aortic tissue to be the average elastic modulus known
from studies like ours and those done elsewhere. So there are those
important assumptions that are made. All those very fancy equa-
tions look as though they would be terrific, but, again, I think
they are assuming the constant blood pressure and they are assum-
ing the average elastic modulus.iovascular Surgery c Volume 145, Number 3S S161
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that the in vivo assessment of wall stress in individual patients,
along with the genetics that Dr Maleic talked about yesterday,
will be the next milestones in our decision making regarding
when to operate. This is a very important point; thank you.
Dr Said A. B. Silliman (Cairo, Egypt). My question is for Drs
Safi and Kouchoukos about reimplanting the lower intercostals and
the first lumbar intersegmental artery. You mentioned 2 tech-
niques: circulatory arrest with deep hypothermia for Dr Kouchou-
kos, and the other technique, used by Dr Safi, without circulatory
arrest. I noticed that Dr Safi pays attention to reimplanting the
lower intercostals. What does Dr Kouchoukos say with regard to
reimplantation?
Dr Kouchoukos.We implant the lower lumbar intersegmental
arteries when they are patent. We are more inclined to do it in pa-
tients with chronic dissection, particularly in the younger patients
who have extensive aneurysms. With respect to the patients who
have severe atherosclerotic disease—the patients Dr Safi was talk-
ing about, those with extent 3 and 4 disease with extensive athero-
sclerosis—it is rare, in our experience, that you find patent
intercostal arteries, at least lower intercostal arteries and lumbars
that can be implanted. And Dr Griepp has challenged the notion
that you need to implant them at all.
In our analysis of our cases, we found no difference in the prev-
alence of paraplegia between the patients in whom we implanted
intercostal arteries and lumbars and those in whom we didn’t.
And I think among the reasons may be that if you look at these pa-
tients with follow-up CTs, many times these vessels are not open
after they have been reimplanted. So I am not sure that we really
know the answer.
Dr Safi.Well, in the past we reimplanted them in anyone, from
T8 to T12. In the last 5 years, I think that Tony Estrera has changed
the practice in our work. Tony, will you tell them how you are us-
ing neuromonitoring?
Dr Estrera. We presented this 2 years ago at this meeting,
a kind of neuromonitoring-guided thoracoabdominal replacement.
In that protocol, we use motor-evoked potentials as well as so-
matosensory-evoked potentials. If we get no change during sur-
gery at the time where we would be working on those intercostal
arteries, we don’t reimplant them. If we don’t ever have a change,
we just ligate them.
When we looked at the data, I think it was from more than 100
cases, it turns out that in 30% of the cases that you could reimplant
T8 to L1, implanting the intercostal arteries allowed us to recover
our motor-evoked potentials. So about 30% of the time it is ben-
eficial to reattach intercostal arteries in the way we do our
operation.
Now, Dr Griepp ligates all intercostal arteries before the aorta
is clamped. So how he does the operation—his model—is a little
bit different. But the way we do the operation, intercostal artery
reattachment was beneficial 30% of the time. So it has been
eliminated 70% of the time, and decreased our operative time.
But the other change we have made concurrently is to use
a loop graft to reattach the intercostal arteries as opposed to an
inclusion patch; we saw a number of intercostal patch aneurysms
in the past.
Dr Kouchoukos. Has your new method reduced the prevalence
of paraplegia?S162 The Journal of Thoracic and Cardiovascular SurDr Estrera.No, not significantly from our previous experience.
We didn’t have enough cases to answer the question. Dr Safi
showed a slide from the article that was published, and the inci-
dence of paraplegia was about 2%. This is a problem with all stud-
ies of paraplegia now: the incidence is fairly low. So you are going
to need a large number of cases to show any difference. The neuro-
monitoring protocol has decreased our overall operative time how-
ever, in that we don’t have to reattach so many intercostal arteries.
Dr Di Luozzo. I just wanted to make a comment. Eric Roselli
doesn’t implant any intercostals when he does hybrid thoracoabdo-
minal cases. So where is the validity of implanting in the open
cases? In our protocol, and as we move on with endovascular re-
pairs, there won’t be any reimplantation of intercostal arteries,
and the evidence is that the patients have a very low incidence
of spinal cord injury.
Mr Cheshire. It probably is worth mentioning some of these
newer techniques, though, for example very long aortic coverage
with stent-grafts that leave a single sac perfusion branch open, al-
lowing the patient to settle for a couple of weeks, and then the per-
fusion branch is closed either permanently or as a trial, and the
spinal cord monitored. Because—as Dr Griepp and I have dis-
cussed, previously—I think that this is an idea that follows directly
from his work of understanding the serial nature of closing off in-
tercostals, even though Krassi Ivancev, who invented it, claims he
didn’t even know that work but just came up with the idea. It’s very
valid, however, and I could see that allowing time between ligation
of intercostals might have a real future.
Dr Roselli. If I could expand on my remarks, although it’s true
that we don’t reimplant intercostals with endovascular repairs, we
do look at the patient’s entire vascular collateral supply to the spi-
nal cord when we assess these patients. There are patients in whom
we feel that the intercostal bed is really important because they
have compromised hypogastrics or something of that sort, and
those patients we will not treat with an endovascular operation
but will send them for open surgery. And so I think, once again,
you have to assess the situation on a patient-by-patient basis.
Dr Coselli. One interesting thing is the issue of delayed para-
plegia. We have in the last 600 cases or so seen a flip. Before,
we would see about two thirds immediate paraplegia versus a third
delayed paraplegia; now, it’s almost the opposite. We are seeing
about two thirds delayed and a third immediate, just stressing
the importance of some of the factors involved with postoperative
care.
We still reattach intercostal arteries. We had an experience with
somewhere around 100 patients in which we used motor-evoked
potentials, trying to duplicate what Jacobs has described, but we
had so many false negatives and false positives that it really didn’t
affect or alter our results enough to continue to use motor-evoked
potentials. If you do use them, there are some issues with anesthe-
sia; there are some concerns with lower extremity ischemia that af-
fect your readings and results, and it’s not very adaptable to deep
hypothermic cases.
Dr Griepp. I will just add a final comment. One thing that
pretty much everyone can agree on is the importance of the hypo-
gastric arteries in the spinal cord circulation. As I said before, I
think that much of the data having to do with the risk factor for
paraplegia with TEVAR and the thoracic aorta with previous ab-
dominal aortic repair probably had very little to dowith the lumbargery c March 2013
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iliacs. I think all of us probably appreciate that as one treats the
thoracoabdominal aorta, closing off the hypogastrics is not a be-
nign procedure. They are probably some of the most important
collateral pathways for spinal cord blood supply.
DrMichael T. Janusz (Vancouver, British Columbia, Canada).
I have a question for Drs Safi and Kouchoukos regarding interpo-
sition grafts for the visceral vessels. Through the years, I have quite
often used an interposition Dacron polyester fabric graft to the left
renal in a thoracoabdominal aneurysm repair, with direct implan-
tation of the other vessels. In the first few years of CT follow-up,
the patency of the interposition graft was fine, but in later films
taken 10 years or more postoperatively, it is not uncommon to
see occlusion of that Dacron graft. I don’t have any numeric
data on it, but whenever I do see that, I am thankful that I didn’t
use an interposition graft on the other renal. Do you have any in-
formation about the long-term follow-up of interposition grafts
in this position?
Dr Kouchoukos.We looked at a series of these patients that we
published several years ago, forwhomwe have follow-up of at least
5 years. In the time since, we have followed these patients up fairly
regularly with imaging, and we have only seen three patients who
developed either stenoses or occlusions. The stenoses were treated
with stents. The one patient with occlusion had some critical event
where he became hypotensive and thrombosed all the branches. In
general, the grafts have stayed patent in our experience, and we ha-
ven’t seen to date any late occlusions. Obviously there is attrition in
this population of elderly patients: they may die and we may not
know about these occlusions. But at least among the ones we
have followed up, we have not seen any significant occlusions.
Dr Safi.We limit the use of side-arm grafts to patients who are
young and have connective tissue disorders. When we need to do it
in a patient with medial degenerative disease, to the renal arteries, I
tend to use a bigger graft, not 8; I use 10 or 12. That is what I
learned from Dr Crawford. And we didn’t have a problem, as
you said.
Dr Griepp. I would add to that. In Dr Spielvogel’s series of tri-
furcation grafts to the arch vessels, I think it is true that we have yet
to see an occluded arch branch graft in annual postoperative CT
scans. Is that still right, David?
Dr David Spielvogel (Valhalla, NY). As far as I know.
Dr Griepp.And almost all of these patients have annual CTs in
our follow-up program. So at least in the arch, occlusion of
a branched graft is extremely unusual.
Dr Vicki Mahan (Worcester, Mass). My question is directed to
all the panel members. What are the indications for TEVAR in the
patient with Marfan syndrome?
Dr Griepp. Craig, you will have fun with this one.
Dr Miller. That’s a very easy question. None.
Dr Coselli. Dr Miller is referring to TEVAR as a primary defin-
itive procedure in Marfan syndrome. But we have used endovascu-
lar repair in some intercostal patch aneurysms, in which basically
you are relining the graft. We have had some patients with extent 4
disease who have had some previous grafts either in the arch or the
very proximal descending in whom we have used TEVAR graft to
graft. Also, I think that you have to give some consideration to life-
saving emergency situations as a bridge, again, depending on your
skills and environment.The Journal of Thoracic and CardDr Elefteriades. I am strongly biased toward open repair even
in the patient without Marfan syndrome, so I am not a good one to
comment on that.
Dr Safi.With me, the answer is none. There is no reason to put
in a stent in a patient with a connective tissue disorder.
Dr Kouchoukos. I would be to the right of Craig Miller on this
one as well. The people who have tried it have had problems with
introduction of retrograde dissections. There is a recent publica-
tion from the University of Florida in which they looked at a group
of patients with Marfan syndrome, and the complication rate was
extraordinary. I think that article provides a good lesson about why
not to do it in patients who have these connective tissue or genet-
ically determined disorders.
DrDi Luozzo. I agreewith Dr Coselli. I think that in emergency
situations it is a good bailout, and also if you have a casewhere you
have a graft to graft situation, if patients have had previous surgery.
Otherwise, in elective cases, perform open surgery.
Mr Cheshire. We think that there are no indications, but we
have done about 12 in our series either because the patient was
very sick at the time or because there were other contraindications
to open surgery. Occasionally, you can get away with it. We ha-
ven’t seen any retrograde dissections, either.
Dr Roselli. I am going to echowhat most of the panel have said,
except for the none part. I think that there is definitely an indication
for stent-grafts in patients with Marfan syndrome, because there is
a certain spectrum of aortic degeneration that we see in these pa-
tients, and the ones who have the entire aorta degenerated often
need a lifetime of operations until the whole aorta has been re-
placed. So I have a whole group of these patients who have under-
gone what we call an ultrahybrid reconstruction, where they have
Dacron polyester fabric grafts sutured into parts of their aorta and
stent-grafts interposed, whether it is for a patch aneurysm or some
other sort of disaster. But we try to put the stent-graft into Dacron.
Dr Kouchoukos. If you can anchor the stent to a graft, I see no
problem there.
Dr Roselli. That is where we have a bunch of cases.
Dr Estrera. I would add none for elective cases, and I do agree
with Eric and Gabe and Joe with regard to an emergency situation.
I think it would be good in an emergency, lifesaving situation, es-
pecially aortoesophageal fistula or aortobronchial fistula: the pa-
tient is bleeding, the patient is dying, put a stent there, allow the
patient to recover, and then come back in a month or so and take
it out and do the definitive operation at that time.
Dr Griepp. So I think the answer is that stents are appropriate
only in the part of the patient with Marfan syndrome that is unaf-
fected by Marfan disease, or when it’s a temporary procedure. Dr
Estrera has to do a certain number of these cases so Dr Safi can
make his films of pulling the stents out.
Dr Santi Trimarchi (San Donato, Italy). My question is for Dr
Elefteriades. I very much enjoyed your presentation. It was fantas-
tic. It looks as though we have a kind of pocket list that we can per-
haps use for the near future to treat very specific patients to prevent
rupture and dissection. We are trying to do a similar study as you
showed with the engineers on the descending section on both seg-
ments, ascending versus descending, and the situation with the de-
scending looks a little bit different. The thickness that we usually
have in the descending aorta samples is very different than in the
ascending aorta: there are fewer elastic fibers, the presence ofiovascular Surgery c Volume 145, Number 3S S163
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we are for descending disease in terms of genes? We don’t have
very specific genes for descending aortic disease. We don’t have
much news about specific medical therapy for descending aortic
disease. And also, these types of functional and anatomic studies
look a little bit different. Can you tell us something more?
Dr Elefteriades. Yes, Santi. I think it is clear that it is really 2
different diseases. From the annulus to the ligamentum arteriosum,
it is a noncalcified, heavily genetic disease without thrombus.
From the ligamentum distally, it is a different disease. It is calci-
fied, arteriosclerotic, there is lots of thrombus, and the thoracic
aorta looks just like the abdominal aorta in that regard. We are
beginning to recognize now that the embryologic origins of the
ascending and the descending aorta are completely different. So
maybe that’s part of the reason for the differences.
I think that you are wise to focus on the mechanical differences
in those 2 segments. We have to remember that the aorta as it
branches is like a tree as it gives off its branches and gets taller.
The aorta doesn’t need to be as strong more distally along its
length. The ascending aorta has 78 lamellae, and the descending
aorta has about 28 lamellae. So it is a completely different kettle
of fish. I think that you raise a very valuable point, that the 2 aortasS164 The Journal of Thoracic and Cardiovascular Surare different, and thus we can expect their engineering character-
istics to be different, and I applaud and encourage you to explore
the mechanical characteristics of the descending aorta.
Dr Pasquale Totaro (Milan, Italy). I have a question for Dr Es-
trera and, of course, all the other doctors. Do you treat acutely even
a traumatic grade 1 or intimal tear, or how do you manage it if you
follow up just with medical therapy?
Dr Estrera. It is a difficult subset of patients, because these are
the ones we don’t put stents in. And again, remember, these are all
shadows; ultrasonography, angiography, and CT are all shadows.
Trying to interpret what happened in that aorta, you see a little
bit of a flap; we call it an intimal tear, we call it a grade 1 injury.
We will treat those medically. But they need to be followed up
closely: there was 1 patient in the series who came back about
a month later with a false aneurysm. So they have to be followed
up. And that is really the challenge of this subset of patients, be-
cause I don’t think that they all need to be treated. I think you
need to follow up them and treat them expectantly in case a prob-
lem occurs. Following these patients up is difficult, however, espe-
cially with TEVAR. As I noted in this presentation, we had
complete radiologic follow-up for only 32% of the patients who
underwent TEVAR.gery c March 2013
